ASH podium presentations

“Small Molecule ST2 inhibitors Cause Reduction of Soluble ST2 and Improve GVHD and Survival In Vivo” Presented by

Chao-Yie Yang, PhD
Research Assistant Professor, Internal Medicine

“Hyperactive Nras and Dose Reduction of Tet2 Collaborate to Dys-Regulate Hematopoietic Stem Cells and Promote Leukemogenesis” Presented by

Xi Jin, PhD
Research Fellow, Hematology and Oncology

“A Comparison of Socioeconomic Factors in Patients Continuing Warfarin Versus Switching to a DOAC” Presented by

Jordan Schaefer, MD
Fellow, Hematology and Medical Oncology

“N-RasG12D-mediated dysregulation of IRE1alpha-Xbp1s signaling promotes pre-leukemic hematopoietic stem cell expansion” Presented by

Lu Liu, PhD
Research fellow, Internal Medicine

on
Thursday, November 17, 2016
12:00 p.m. – 1:00 p.m.
in
M3330, Med Sci 1

Contact: 7-1417
To record attendance, go to www.umhscme.com
The Event Name and ID for this meeting are “Hematology/Oncology Research Conference – 05023”

Chao-Yie Yang, Xi Jin, Jordan Schaefer and Lu Liu have had no commercial relationships relevant to this presentation.
Dr. Rae faculty planner for this activity has had no relevant financial relationships.
Dr. Kalemkerian, faculty planner for this activity, has received grant/research support from Merck, OncoMed, Astex, Pfizer, Novartis, Millennium and GlaxoSmithKline.

The objective of this series is to inform physicians and other health care professionals of advances and their scientific basis across various fields within Hematology/Oncology.
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCMCE) to provide continuing medical education for physicians.
The University of Michigan Medical School designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.